Join

Compare · CDAK vs RGC

CDAK vs RGC

Side-by-side comparison of Codiak BioSciences Inc. (CDAK) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CDAK and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • RGC is the larger of the two at $11.74B, about 93.8x CDAK ($125.2M).
  • RGC has hit the wire 6 times in the past 4 weeks while CDAK has been quiet.
  • CDAK has more recent analyst coverage (2 ratings vs 0 for RGC).
MetricCDAKRGC
Company
Codiak BioSciences Inc.
Regencell Bioscience Holdings Limited
Price
$0.06-53.11%
$23.86+2.56%
Market cap
$125.2M
$11.74B
1M return
-
-18.06%
1Y return
-
+48.60%
Sector
Health Care
Health Care
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NASDAQ
NASDAQ
IPO
2020
2021
News (4w)
0
6
Recent ratings
2
0
CDAK

Codiak BioSciences Inc.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest CDAK

Latest RGC